BAX and breast cancer: Similarly, Maroufi et al. [97] reported that myricetin-loaded nanostructured lipid carriers (NLCs) enhanced the anticancer effect of DXT via the downregulation of Mcl-1, survivin, and cyclin B1 and the upregulation of Bid and Bax in MDA-MB231 breast cancer cells.